Literature DB >> 3639908

In vitro generation of an HTLV-III variant by neutralizing antibody.

M Robert-Guroff, M S Reitz, W G Robey, R C Gallo.   

Abstract

Transmission and culture of "parental" virus (HTLV-III) from H9 cells transfected with the cloned isolate (lambda HXB-2D) in human serum possessing HTLV-III neutralizing antibody selected for a "variant" that was not neutralized by the selecting serum but was neutralized by another antibody-positive serum "Control" virus, selected in serum lacking neutralizing antibody, and the variant showed highly similar tryptic peptide maps of the major envelope glycoprotein, and no changes in restriction enzyme patterns of viral DNA. These findings show that HTLV-III type-specific neutralizing antibodies occur, can influence the propagation of variant viruses that may arise, and presumably result from minor changes in the eliciting antigen. The extent to which such type-specific neutralizing antibodies influence immune surveillance against HTLV-III infection in vivo, a question with relevance to future vaccination attempts, remains to be determined. Nucleotide sequencing of the control and variant envelope genes may elucidate a region important for virus neutralization and vaccine development.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3639908

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Substitutions in the receptor-binding domain of the avian sarcoma and leukosis virus envelope uncouple receptor-triggered structural rearrangements in the surface and transmembrane subunits.

Authors:  R Damico; L Rong; P Bates
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo.

Authors:  Shuji Sato; Eloisa Yuste; William A Lauer; Eun Hyuk Chang; Jennifer S Morgan; Jacqueline G Bixby; Jeffrey D Lifson; Ronald C Desrosiers; Welkin E Johnson
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

Review 3.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

4.  Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.

Authors:  T Muster; R Guinea; A Trkola; M Purtscher; A Klima; F Steindl; P Palese; H Katinger
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

5.  Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways.

Authors:  B A Watkins; M S Reitz; C A Wilson; K Aldrich; A E Davis; M Robert-Guroff
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.

Authors:  E J Park; L K Vujcic; R Anand; T S Theodore; G V Quinnan
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

7.  Homogenous HIV-1 subtype B quasispecies in Brazilian men and women recently infected via heterosexual transmission.

Authors:  Nancy Lima Gouveia; Michelle Camargo; Marcos Montani Caseiro; Luiz Mario Ramos Janini; Maria Cecilia Araripe Sucupira; Ricardo Sobhie Diaz
Journal:  Virus Genes       Date:  2014-02-14       Impact factor: 2.332

8.  The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope.

Authors:  C Wilson; M S Reitz; K Aldrich; P J Klasse; J Blomberg; R C Gallo; M Robert-Guroff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

9.  Recombinational analysis of a natural noncytopathic human immunodeficiency virus type 1 (HIV-1) isolate: role of the vif gene in HIV-1 infection kinetics and cytopathicity.

Authors:  K Sakai; X Y Ma; I Gordienko; D J Volsky
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

10.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.